Abstract
Prophylaxis is the globally accepted standard of care for persons with haemophilia and presents many advantages over episodic treatment. The prophylaxis benefits include bleed reduction, reduction in musculoskeletal complications and improvement in the quality of life. The currently evolving novel therapies for the management of haemophilia has ushered a new era characterized by improved prophylaxis targets and outcomes. These redefined targets and outcomes have necessitated the need to also redefine prophylaxis. In this state-of-the-art review, we redefine prophylaxis in the modern era by revisiting its definition, presenting data to support higher trough levels to achieve with prophylaxis and introducing steady-state haemostasis as a possible new target for prophylaxis.
Author supplied keywords
Cite
CITATION STYLE
Mahlangu, J. N., Blanchette, V., & Klamroth, R. (2021). Redefining prophylaxis in the modern era. Haemophilia, 27(S3), 21–27. https://doi.org/10.1111/hae.14035
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.